Blood Based Articles & Analysis: Older
50 news found
The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark’s blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe’s screen-eligible population who are most likely to benefit from a CT ...
Business Update Highlights “Our Q2 results demonstrate BioMark’s continued efforts to advance our technology platform with exceptional clinical data, expand our global partnerships, and accelerating the commercialization of its early lung cancer blood-based assay despite a challenging macro environment” said CEO Rashid Bux. ...
This new multicenter study will serve multiple purposes including: the identification of patients eligible for recruitment in STALICLA’s upcoming STP1 and STP2 Phase 2 studies planed in 2023; the validation of blood-based biomarkers for each subgroup; the enrichment of STALICLA’s database with comprehensive clinical and biological datasets to ...
BySTALICLA
Sepset’s technology, which is based on extensive and ground-breaking work led by renowned University of British Columbia (UBC) researcher Dr. ...
Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis. Sepset’s blood-based test works by detecting a unique biomarker signature based on the body’s immune response rather than the presence of a pathogen. ...
Similar to our category-altering cell-free DNA-based prenatal test, UNITY Screen™ , our liquid biopsy products aim to achieve a level of performance and differentiation unmatched in the field. In particular, our QCT technology provides precise tumor burden quantification without needing the tumor tissue. We believe that blood-based ...
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and ...
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. ...
Rocío Arroyo, researcher, and CEO of Amadix, leads the team that has created an innovative blood-based test that can detect if a healthy person will develop a malignant colon tumour in the future. ...
ByAmadix
“We are honored that NCCN, an organization that provides valuable guidelines based on the latest evidence and expert consensus, now includes our IsoPSA test in its guidelines for prostate cancer early detection,” said Arnon Chait, Ph.D., Chief Executive Officer at Cleveland Diagnostics. ...
(Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). ...
Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy. Blood-based test holds potential for broad applicability for the management of patients with cancer. Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for ...
Commenting on the lawsuit, John Saia, the company’s SVP, General Counsel and Corporate Secretary, said: “At Guardant Health, our mission for the last 10 years has been to develop groundbreaking blood tests that improve cancer care and save patients’ lives. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and outcomes.” “We’re very pleased that providers are not only willing to insert IsoPSA into their current diagnostic workflow, but also change their behavior ...
--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. ...
“Tissue biopsies can be difficult to obtain, time-consuming, and lead to complications, all of which can delay a patient’s treatment. Our blood-based tests can overcome these barriers and provide fast and actionable information to help guide treatment decisions across the continuum of ...
Patients will also undergo the OncoFOLLOW™ liquid biopsy test at different stages of their treatment journey. This personalized blood-based test will help clinicians to closely monitor a patient’s response to treatment and take immediate action in the event of treatment resistance or new mutations. ...
Ron Winston, President, Institute for Human Genetics and Biochemistry said, “We are pleased with these pre-clinical results, which have further increased our confidence in the promising potential of Alphataxin to treat cancers and immune deficiencies. Based on this positive data, the company plans to raise additional capital to rapidly advance the Alphataxin development ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. ...
Rather than relying on contrast dye and X-ray based imaging to help guide the implant placement, Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, performed the procedure using ultrasound-based 4D holographic imaging, which provides an image so clear that potentially harmful ...